BioStem Technologies to Present at the Planet MicroCap Las Vegas 2026 Conference
Rhea-AI Summary
BioStem Technologies (OTC:BSEM), a regenerative medicine company focused on perinatal tissue allograft products, announced that management will present at the Planet MicroCap Las Vegas 2026 Conference.
The presentation is scheduled for Wednesday, June 17, 2026, at 3:00 PM ET, with live and archived webcasts available on the company’s investor relations website.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BSEM
On the day this news was published, BSEM declined 2.04%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
POMPANO BEACH, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Planet MicroCap Las Vegas 2026 Conference.
BioStem is scheduled to present on Wednesday, June 17, 2026, at 3:00 PM ET. Interested parties may access live and archived webcasts of presentations on the “investors” section of the Company’s website at: ir.biostemtechnologies.com.
About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a publicly traded, biomedical innovator, focused on developing, manufacturing and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages its industry-leading proprietary BioRetain®, CryoTek® and SteriTek® processing technologies, designed to optimize the preservation of the natural properties of these tissues, supporting their use in clinical settings. Its allografts are used by clinicians across a wide range of specialties. With a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint, BioStem is committed to advancing innovation in regenerative medicine.
BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established in compliance with current Good Tissue Practices (“cGTP”) and current Good Manufacturing Practices (“cGMP”). BioStem’s portfolio of quality brands includes its Neox®, Clarix®, VENDAJE® and American Amnion™ product lines.
Join BioStem’s Distribution List & Social Media:
To follow the latest developments at BioStem, sign up for the Company’s email distribution list HERE, and follow us on X and LinkedIn.
Contact BioStem:
Website: www.biostemtechnologies.com
E-Mail: pr@biostemtech.com
X: @BSEM_Tech
Facebook: BioStemTechnologies
Phone: 954-380-8342
Investor Relations:
Philip Trip Taylor, Gilmartin
Group E-Mail: ir@biostemtech.com
Public Relations:
Jennifer Horton, Relevance
jennifer@relevance.com
